GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (STU:AT2) » Definitions » Short Percentage of Float

Atara Biotherapeutics (STU:AT2) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is Atara Biotherapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Atara Biotherapeutics's Short Percentage of Float

For the Biotechnology subindustry, Atara Biotherapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atara Biotherapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Short Percentage of Float falls into.


Atara Biotherapeutics (STU:AT2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (STU:AT2) » Definitions » Short Percentage of Float
Comparable Companies
PRAX PDSB VAXX ABOS PEPG MRSN LRMR ALT ADAP RPTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ATRA:USA AT2:Germany
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Website
https://www.atarabio.com
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (STU:AT2) Headlines

No Headlines